Matches in Nanopublications for { ?s ?p "[Patients suffering from the metabolic disease hereditary tyrosinemia type I (HT1), caused by fumarylacetoacetate hydrolase deficiency, have a high risk of developing liver cancer.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine."@en ?g. }
Showing items 1 to 14 of
14
with 100 items per page.
- NP644051.RADXyUSbiEIpdQABkDTnA2qnkYaxRBwJyTm5FhH5ERs0A130_assertion description "[Patients suffering from the metabolic disease hereditary tyrosinemia type I (HT1), caused by fumarylacetoacetate hydrolase deficiency, have a high risk of developing liver cancer.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP644051.RADXyUSbiEIpdQABkDTnA2qnkYaxRBwJyTm5FhH5ERs0A130_provenance.
- NP669377.RACoppkHDohEhQvwr0oGHrDeqqWwbNop53cD1hdfC9pe0130_assertion description "[Patients suffering from the metabolic disease hereditary tyrosinemia type I (HT1), caused by fumarylacetoacetate hydrolase deficiency, have a high risk of developing liver cancer.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP669377.RACoppkHDohEhQvwr0oGHrDeqqWwbNop53cD1hdfC9pe0130_provenance.
- NP870258.RAWxS2buc16GUA-_si0pTSeCWbtAV-LNV-otCpfRvQvkI130_assertion description "[Patients suffering from the metabolic disease hereditary tyrosinemia type I (HT1), caused by fumarylacetoacetate hydrolase deficiency, have a high risk of developing liver cancer.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP870258.RAWxS2buc16GUA-_si0pTSeCWbtAV-LNV-otCpfRvQvkI130_provenance.
- assertion description "[Patients suffering from the metabolic disease hereditary tyrosinemia type I (HT1), caused by fumarylacetoacetate hydrolase deficiency, have a high risk of developing liver cancer.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
- assertion description "[Patients suffering from the metabolic disease hereditary tyrosinemia type I (HT1), caused by fumarylacetoacetate hydrolase deficiency, have a high risk of developing liver cancer.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
- assertion description "[Patients suffering from the metabolic disease hereditary tyrosinemia type I (HT1), caused by fumarylacetoacetate hydrolase deficiency, have a high risk of developing liver cancer.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
- assertion description "[Patients suffering from the metabolic disease hereditary tyrosinemia type I (HT1), caused by fumarylacetoacetate hydrolase deficiency, have a high risk of developing liver cancer.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
- NP393833.RAfx59ck5H_dk51zkAHM6r62LJFXuaErohvLtVG6RStdg130_assertion description "[Patients suffering from the metabolic disease hereditary tyrosinemia type I (HT1), caused by fumarylacetoacetate hydrolase deficiency, have a high risk of developing liver cancer.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP393833.RAfx59ck5H_dk51zkAHM6r62LJFXuaErohvLtVG6RStdg130_provenance.
- NP329101.RAYjtXodVUNxybHMBdA75D8y5hm3bg06v27i9u_Hi0sIA130_assertion description "[Patients suffering from the metabolic disease hereditary tyrosinemia type I (HT1), caused by fumarylacetoacetate hydrolase deficiency, have a high risk of developing liver cancer.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP329101.RAYjtXodVUNxybHMBdA75D8y5hm3bg06v27i9u_Hi0sIA130_provenance.
- NP329103.RABIkCT1opvFdti3xXLX7DyETovoqqhPbrk_C6OmwcsMA130_assertion description "[Patients suffering from the metabolic disease hereditary tyrosinemia type I (HT1), caused by fumarylacetoacetate hydrolase deficiency, have a high risk of developing liver cancer.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP329103.RABIkCT1opvFdti3xXLX7DyETovoqqhPbrk_C6OmwcsMA130_provenance.
- NP329102.RAknfwqrppC86J7ubtehMYeS1MIRIrkj9mzrIFvPpL5kc130_assertion description "[Patients suffering from the metabolic disease hereditary tyrosinemia type I (HT1), caused by fumarylacetoacetate hydrolase deficiency, have a high risk of developing liver cancer.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP329102.RAknfwqrppC86J7ubtehMYeS1MIRIrkj9mzrIFvPpL5kc130_provenance.
- NP329104.RAjnP3vTOF2Dr_f7XuSmYMO7dIO2rV0Jpfv5HKYhAyYtA130_assertion description "[Patients suffering from the metabolic disease hereditary tyrosinemia type I (HT1), caused by fumarylacetoacetate hydrolase deficiency, have a high risk of developing liver cancer.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP329104.RAjnP3vTOF2Dr_f7XuSmYMO7dIO2rV0Jpfv5HKYhAyYtA130_provenance.
- NP393862.RA_2bV2bd97ub3r--FAhN-QHEgQEqETiAWUexjHY14QO0130_assertion description "[Patients suffering from the metabolic disease hereditary tyrosinemia type I (HT1), caused by fumarylacetoacetate hydrolase deficiency, have a high risk of developing liver cancer.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP393862.RA_2bV2bd97ub3r--FAhN-QHEgQEqETiAWUexjHY14QO0130_provenance.
- NP393864.RA0ODwPxS1BLkew9B3iOBcf1qBMHKpsVhUEAY47Bdf0O4130_assertion description "[Patients suffering from the metabolic disease hereditary tyrosinemia type I (HT1), caused by fumarylacetoacetate hydrolase deficiency, have a high risk of developing liver cancer.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP393864.RA0ODwPxS1BLkew9B3iOBcf1qBMHKpsVhUEAY47Bdf0O4130_provenance.